查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965990

流感藥物市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類型、分銷管道、地區和競爭格局分類，2021-2031年

Influenza Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球流感治療市場預計將從 2025 年的 9.7113 億美元成長到 2031 年的 14.1622 億美元，複合年成長率為 6.49%。

該領域涵蓋抗病毒療法和預防性疫苗，旨在降低季節性流感和流行性流感病毒株的嚴重程度。推動該市場成長要素是全球呼吸道病毒感染疾病的增加以及全球人口老化導致的易感性上升。此外，各國政府為應對疫情而製定的嚴格規定以及對醫療物資的策略性儲備，也為市場發展的永續發展奠定了基礎。

市場概覽
預測期 2027-2031
市場規模：2025年 9.7113億美元
市場規模：2031年 1,416,220,000 美元
複合年成長率：2026-2031年 6.49%
成長最快的細分市場 奧司他韋
最大的市場 北美洲

病毒抗原漂移速度極快，這是市場擴張的一大障礙，隨著時間的推移，這可能會降低現有治療方法和預防措施的有效性。儘管面臨這項持續挑戰，製藥業仍致力於創新，並大力投資對抗病毒抗藥性。據國際藥品製造商協會聯合會（IFPMA）稱，到2025年，將有超過30種流感疫苗候選產品進入臨床試驗階段，這表明該領域正致力於應對不斷演變的生物威脅。

市場促進因素

政府的戰略儲備和應對疫情的舉措是市場的主要促進因素，各國政府正積極確保疫苗供應，以應對通用感染疾病的威脅。公共衛生機構優先資助新技術，以確保在疫情爆發時能夠快速生產疫苗，從而降低製藥公司的商業風險。例如，2024年7月，美國衛生與公共服務部宣布，生物醫學高級研究與發展局已向Modena Pharmaceuticals公司撥款約1.76億美元，用於支持其開發基於mRNA技術的流感大流行疫苗。這凸顯了疫苗研發策略朝向能夠快速應對新病毒株的靈活平台轉變。

此外，季節性流感在全球範圍內的發病率不斷上升，以及禽流感病毒株帶來的迫在眉睫的威脅，正在推動市場成長，因為這些因素都要求建立健全的治療和預防藥物供應鏈。高感染率給醫療保健系統帶來了沉重的負擔，並確保了不同人群對有效干預措施的持續需求。根據美國疾病管制與預防中心 (CDC) 2024 年 10 月的報告，2023-2024 年流感季期間，美國估計有 3,500 萬人感染流感。為了因應類似的跨國威脅，國際採購機制也不斷擴大。例如，2024 年，CCS Seqirus 與歐盟委員會簽訂了一份契約，供應多達 66.5 萬劑動物性流感疫苗，以降低潛在的疫情風險。

市場挑戰

抗原漂移的快速發展是全球流感治療市場持續成長的主要障礙。這種持續的基因演化機制會改變病毒的表面蛋白，使其能夠頻繁地逃避先前感染或疫苗接種所建立的免疫力。因此，現有抗病毒藥物和疫苗的臨床效用迅速下降，可能導致治療效果降低和公眾信心下降。這種不穩定性迫使製造商陷入持續且資源密集的產品重新設計和臨床試驗循環，造成巨大的財務風險和業務不確定性，阻礙市場長期擴張。

這項挑戰的嚴峻性體現在這尚未解決的健康威脅所造成的巨大經濟影響。由於即使存在治療方法，病毒也無法被徹底清除，因此持續高成本的疫情爆發給醫療系統帶來了沉重負擔。根據國際藥品製造商協會聯合會（IFPMA）預測，到2024年，歐盟成年人季節性流感造成的經濟負擔預計將高達每年140億歐元。如此巨大的經濟負擔凸顯了市場在克服病毒不斷進化的抗藥性方面所面臨的困境，因為即使是已有的治療方法也難以在病毒不斷變異的靶點面前保持療效。

市場趨勢

新冠病毒和流感聯合疫苗的開發平臺不斷擴展，正迅速改變市場競爭格局，提供簡化的免疫接種方案，有效解決疫苗接種疲勞和物流效率低下等問題。製造商正專注於研發這些雙抗原候選疫苗，以提高患者依從性並簡化年度免疫接種程序，尤其適用於需要抵抗多種呼吸道病原體的老年族群。這種整合方案兼顧了疫苗的有效性和便利性，從而提升了市場價值。例如，2024年6月，Moderna公司報告稱，其在研的mRNA-1083疫苗對三種流感病毒株和SARS-CoV-2病毒均產生了統計學意義上的顯著更高的免疫反應。在65歲及以上成年人中，該疫苗對H1N1病毒株的幾何平均免疫反應率達1.155，高於已已通過核准的對照疫苗。

無針鼻腔給藥系統的出現標誌著醫療模式向去中心化模式的重大轉變，減少了對臨床基礎設施的依賴，並克服了侵入性給藥的障礙。透過證明自我給藥方案的有效性，該行業正在擴大家庭和藥房的網路基地台，從而提高猶豫接種人群和兒童的疫苗接種率。據Astra Zeneca稱，其用於自我給藥的FluMist已於2024年9月核准FDA批准，可用性研究表明，18至49歲的目標用戶100%能夠完成全劑量給藥，證實了這種給藥方式具有廣泛應用的潛力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球流感藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物類型（Ribavirin、奧司他韋、瑞樂沙、帕拉米韋、流感疫苗）
    • 分銷通路（醫院藥局、零售藥局、線上通路）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美流感藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲流感藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區流感藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲流感藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美流感藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球流感藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • FACCUSA Laboratories Inc
  • Lonza Group Ltd
  • Bristol-Myers Squibb Co
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novo Nordisk A/S
  • Sanofi SA
  • Bayer AG
  • Banting Medical Inc
  • Cipla Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18996

The Global Influenza Drugs Market is projected to expand from USD 971.13 Million in 2025 to USD 1416.22 Million by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 6.49%. This sector comprises antiviral therapeutics and prophylactic vaccines aimed at mitigating the severity of both seasonal and pandemic influenza strains. The market is primarily driven by the rising global prevalence of respiratory viral infections and the increased susceptibility of an aging global population. Furthermore, stringent government mandates regarding pandemic preparedness, along with the strategic stockpiling of medical countermeasures, provide a consistent foundation for continued market development.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 971.13 Million
Market Size 2031USD 1416.22 Million
CAGR 2026-20316.49%
Fastest Growing SegmentOseltamivir
Largest MarketNorth America

A major obstacle to broader market expansion is the rapid antigenic drift of the virus, which can render existing treatments and preventive measures less effective over time. Despite this persistent challenge, the pharmaceutical industry remains committed to innovation and investing heavily to combat viral resistance. According to the International Federation of Pharmaceutical Manufacturers and Associations, there are over 30 influenza vaccine candidates in active clinical trials in 2025, underscoring the sector's dedication to addressing these evolving biological threats.

Market Driver

Strategic government stockpiling and pandemic preparedness initiatives serve as a primary catalyst for the market, with authorities actively securing vaccine supplies to counter zoonotic threats. Public health agencies are prioritizing funding for new technologies to guarantee rapid manufacturing capabilities during outbreaks, thereby reducing commercial risks for pharmaceutical developers. For example, the U.S. Department of Health and Human Services announced in July 2024 that the Biomedical Advanced Research and Development Authority awarded Moderna approximately USD 176 million to support the development of an mRNA-based pandemic influenza vaccine, highlighting a strategic shift toward flexible platforms capable of quickly addressing novel viral strains.

Additionally, the increasing global incidence of seasonal influenza and the looming threat of avian strains drive market growth by necessitating robust supply chains for therapeutics and preventatives. High transmission rates result in significant medical burdens, ensuring consistent demand for effective interventions across various demographics. According to the Centers for Disease Control and Prevention's October 2024 report, there were an estimated 35 million influenza illnesses in the United States during the 2023-2024 season. To address similar cross-border threats, procurement mechanisms are expanding internationally; for instance, CSL Seqirus secured an agreement in 2024 to supply the European Commission with up to 665,000 doses of zoonotic influenza vaccine to mitigate potential outbreak risks.

Market Challenge

Rapid antigenic drift represents a primary barrier to the sustained growth of the Global Influenza Drugs Market. This mechanism of constant genetic evolution modifies the virus's surface proteins, frequently allowing it to evade immunity established by prior exposure or vaccination. Consequently, the clinical utility of existing antiviral drugs and vaccines can diminish swiftly, leading to reduced therapeutic effectiveness and lower public confidence. This volatility forces manufacturers into a continuous, resource-intensive cycle of product reformulation and clinical testing, creating significant financial risks and operational uncertainties that hinder long-term market expansion.

The severity of this challenge is illustrated by the substantial economic impact of this unresolved health threat. The inability to permanently neutralize the virus results in persistent, high-cost outbreaks that burden healthcare systems, even when therapeutics are available. According to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the economic burden of seasonal influenza among adults in the European Union was reported to reach up to €14 billion annually in 2024. This heavy financial toll underscores the difficulty the market faces in overcoming the virus's evolutionary resilience, as even established treatments struggle to maintain their value against constantly shifting viral targets.

Market Trends

The pipeline expansion of combined COVID-19 and influenza vaccines is rapidly reshaping the competitive landscape by offering streamlined immunization solutions that address vaccine fatigue and logistical inefficiencies. Manufacturers are focusing on these dual-antigen candidates to improve patient compliance and simplify annual vaccination schedules, especially for older adults who need protection against multiple respiratory pathogens. This integration drives market value by combining efficacy with convenience; for instance, Moderna reported in June 2024 that its investigational mRNA-1083 vaccine elicited statistically significantly higher immune responses against three influenza strains and SARS-CoV-2, achieving a Geometric Mean Ratio of 1.155 for the H1N1 strain in adults aged 65 and older compared to licensed comparators.

The emergence of needle-free and intranasal drug delivery systems marks a major shift toward decentralized care models, reducing reliance on clinical infrastructure and overcoming barriers associated with invasive administration. By validating self-administered options, the industry is extending access points to homes and pharmacies, potentially increasing coverage rates among hesitant demographics and pediatric populations. According to AstraZeneca, in September 2024, the FDA approval of FluMist for self-administration was supported by usability studies demonstrating that 100% of intended users aged 18 to 49 could successfully administer a full dose, confirming the feasibility of this delivery method for widespread public use.

Key Market Players

  • FACCUSA Laboratories Inc
  • Lonza Group Ltd
  • Bristol-Myers Squibb Co
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novo Nordisk A/S
  • Sanofi S.A
  • Bayer AG
  • Banting Medical Inc
  • Cipla Limited

Report Scope

In this report, the Global Influenza Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Influenza Drugs Market, By Drug Type

  • Ribavirin
  • Oseltamivir
  • Relenza
  • Peramivir
  • Influenza Vaccines

Influenza Drugs Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channel

Influenza Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Influenza Drugs Market.

Available Customizations:

Global Influenza Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Influenza Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Ribavirin, Oseltamivir, Relenza, Peramivir, Influenza Vaccines)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Influenza Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Influenza Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Influenza Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Influenza Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Influenza Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Influenza Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Influenza Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Influenza Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Influenza Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Influenza Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Influenza Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Influenza Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Influenza Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Influenza Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Influenza Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Influenza Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Influenza Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Influenza Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Influenza Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Influenza Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Distribution Channel

10. South America Influenza Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Influenza Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Influenza Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Influenza Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Influenza Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. FACCUSA Laboratories Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Lonza Group Ltd
  • 15.3. Bristol-Myers Squibb Co
  • 15.4. Pfizer Inc.
  • 15.5. GlaxoSmithKline plc
  • 15.6. Novo Nordisk A/S
  • 15.7. Sanofi S.A
  • 15.8. Bayer AG
  • 15.9. Banting Medical Inc
  • 15.10. Cipla Limited

16. Strategic Recommendations

17. About Us & Disclaimer